GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » EBIT

Diamyd Medical AB (OSTO:DMYD B) EBIT : kr-151.84 Mil (TTM As of Aug. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB EBIT?

Diamyd Medical AB's earnings before interest and taxes (EBIT) for the three months ended in Aug. 2024 was kr-51.82 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Aug. 2024 was kr-151.84 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Diamyd Medical AB's annualized ROC % for the quarter that ended in Aug. 2024 was -257.59%. Diamyd Medical AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Aug. 2024 was -393.82%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Diamyd Medical AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Aug. 2024 was -10.11%.


Diamyd Medical AB EBIT Historical Data

The historical data trend for Diamyd Medical AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB EBIT Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.24 60.50 -103.26 -116.07 -151.84

Diamyd Medical AB Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.51 -31.19 -28.76 -40.08 -51.82

Competitive Comparison of Diamyd Medical AB's EBIT

For the Biotechnology subindustry, Diamyd Medical AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's EV-to-EBIT falls into.



Diamyd Medical AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-151.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diamyd Medical AB  (OSTO:DMYD B) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Diamyd Medical AB's annualized ROC % for the quarter that ended in Aug. 2024 is calculated as:

ROC % (Q: Aug. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: May. 2024 ) + Invested Capital (Q: Aug. 2024 ))/ count )
=-186.18 * ( 1 - 0% )/( (72.164 + 72.393)/ 2 )
=-186.18/72.2785
=-257.59 %

where

Invested Capital(Q: May. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=248.195 - 13.648 - ( 162.383 - max(0, 20.683 - 183.439+162.383))
=72.164

Invested Capital(Q: Aug. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=217.038 - 25.526 - ( 132.366 - max(0, 40.025 - 159.144+132.366))
=72.393

Note: The Operating Income data used here is four times the quarterly (Aug. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Diamyd Medical AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Aug. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Aug. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: May. 2024  Q: Aug. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-207.264/( ( (55.902 + max(-20.645, 0)) + (49.357 + max(-17.241, 0)) )/ 2 )
=-207.264/( ( 55.902 + 49.357 )/ 2 )
=-207.264/52.6295
=-393.82 %

where Working Capital is:

Working Capital(Q: May. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.037 + 0 + 0.00099999999997635) - (13.648 + 0 + 7.035)
=-20.645

Working Capital(Q: Aug. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.023 + 0 + 22.761) - (25.526 + 0 + 14.499)
=-17.241

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Aug. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Diamyd Medical AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Aug. 2024 )
=-151.842/1501.264
=-10.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diamyd Medical AB EBIT Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
N/A
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines